GSK PLC closed 14.28% short of its 52-week high of £16.79, which the company reached on September 9th.

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in ...

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Property developer Hadley Group has sent in its application for a 13-acre redevelopment of the former GSK headquarters in ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

Developer Hadley Property Group has lodged a hybrid planning application to redevelop the flagship former GlaxoSmithKline ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

A new pill that combats antibiotic-resistant strains of gonorrhoea is closer to US approval, after the FDA accepted GSK’s ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...